<DOC>
	<DOCNO>NCT01520987</DOCNO>
	<brief_summary>To assess pharmacokinetics BIA 9-1067 healthy Japanese subject</brief_summary>
	<brief_title>Pharmacokinetics BIA 9-1067 Healthy Japanese Caucasian Subjects</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled , multiple ascend dose , parallel-group , pharmacokinetic ( PK ) pharmacodynamic ( PD ) study</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<criteria>Men nonlactating nonpregnant woman ; Caucasian Japanese subject . Caucasian subject subject European descent ; Japanese subject must first second generation . Generations define follow : 1 . First generation Japanese subject may live outside Japan bear Japan parent Japanese descent . 2 . Second generation Japanese subject bear outside Japan first generation Japanese parent . Aged 18 65 year ; Body weight ≥50 kg ; Within BMI range 18.5 30 kg/m2 , inclusive ; Healthy , determine Investigator basis medical history , physical examination , clinical laboratory test result , vital sign , 12lead ECG . Creatinine ALT level must strictly within normal range eligibility Checkin ; Women nonchildbearing potential must surgically sterile ( hysterectomy , oophorectomy , tubal ligation ) postmenopausal ≥1 year ; Women childbearing potential must use effective nonhormonal method contraception ( intrauterine device intrauterine system ; condom occlusive cap [ diaphragm cervical vault cap ] spermicidal foam gel film cream suppository ; true abstinence ; vasectomize male partner , provide sole partner subject ) period least 1 month dose administration . Women childbearing potential must negative pregnancy test result within 48 hour start first investigational medicinal product ( IMP ) administration . Hormonal contraceptive allow effect BIA 9 1067 metabolism hormonal contraceptive vice versa yet know ; Nonsmokers , define smoke ≤10 cigarette per week 3 month prior dose , abstain smoke 7 day prior Checkin , negative cotinine level ≤500 ng/mL Checkin ; Have high probability compliance completion study , opinion Investigator ; Able comprehend willing sign ICF . Presence history disorder may prevent successful completion study ; History multiple and/or severe allergy drug food history anaphylactic reaction ; Known suspect allergy adverse drug reaction trial product relate product ( eg , tolcapone entacapone ) ; History alcoholism excessive daily alcohol consumption within past year . Excessive alcohol consumption regard average weekly intake 14 unit woman 21 unit men ( 1 unit alcohol = 8 10 g approximately equivalent 1 glass wine 250 mL beer standard measure spirit ) ; Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease , judge Investigator Sponsor 's Medical Monitor ; Any clinically important deviation normal limit physical examination , vital sign , 12lead ECGs , judge Investigator Sponsor 's Medical Monitor ; Acute disease state ( eg , nausea , vomit , fever , diarrhea ) within 7 day Study Day 1 ; Positive serologic finding HIV antibody , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C virus antibody ( antiHCV ) ; Positive screen drug abuse alcohol ; Recent history presence disorder may interfere absorption , distribution , metabolism , excretion BIA 9 1067 ; Positive pregnancy test result WOCBP ; Consumption caffeinecontaining product ( eg , coffee , tea , chocolate , cola ) , grapefruit , grapefruitcontaining product , alcoholic beverage 48 hour Study Day 1 Discharge ( Day 16 ) ; Involvement investigational study type within 30 day BIA 91067 administration ; Donation blood within 90 day Study Day 1 ; Use prescription drug within 30 day IMP administration unless deem acceptable Principal Investigator ( PI ) Medical Monitor ; Use overthecounter drug include herbal supplement ( except occasional use acetaminophen vitamin ≤100 % recommend daily allowance ) within 14 day Study Day 1 unless deem acceptable PI Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>